Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03029429 · ClinicalTrials.gov registry record · Phase 2

Theophylline Treatment for Pseudohypoparathyroidism

A Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.

Active
Registry status
Phase 2
Development phase
29
Enrollment target
1
Study location

NCT03029429 is a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03029429, a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.

Interventions

  • DRUG Theophylline
  • DRUG Placebos

Study Locations (1)

Tennessee

  • Ashley Shoemaker - Nashville

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2018-09-01
Est. Completion 2026-12-01
Phase Phase 2

What the Registry Record Tells You About NCT03029429

The ClinicalTrials.gov registry entry for NCT03029429 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Albright Hereditary Osteodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Theophylline is the first listed.

NCT03029429 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03029429 about?

NCT03029429 is a clinical study titled "Theophylline Treatment for Pseudohypoparathyroidism". Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The i...

What is the current status of trial NCT03029429?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-09-01. Estimated completion is 2026-12-01.

What conditions does trial NCT03029429 study?

This clinical trial studies the following conditions: Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism.

What interventions are being tested in trial NCT03029429?

The interventions under investigation include: Theophylline (DRUG), Placebos (DRUG).

Who is sponsoring clinical trial NCT03029429?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03029429 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Albright Hereditary Osteodystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.